BCL2 and B-cell non-Hodgkin lymphoma: To address these issues, we systematically studied the clinicopathologic features of 157 patients with MYC/BCL2 DHL including 108 with de novo disease and 49 patients with a history of low-grade B-cell lymphoma, mostly FL.